VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the treatment – called trontinemab – could be the ...

Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infectionsStudy completion expected in ...

Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infectionsStudy completion expected in Q1 2028 Allschwil, Switzerland, July 29, 2025 ...

As early as 2005, Gritz and colleagues drew attention to clinical trialists missing the potential impact of tobacco use on cancer treatment outcomes, as smoking status was rarely recorded in cancer ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Shares in Celcuity climbed by 233.76% at market open on 28 July after it reported the Phase III breast cancer data.

A team of Toronto researchers has received Health Canada approval to conduct clinical trials for a novel class of ...

A research project led by the Ineos Oxford Institute for antimicrobial research (IOI) to study the cause and impact of ...

Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects ...